Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

ABSTRACT: Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) and is active against many HIV type 1 PR variants resistant to earlier-generation PIs. Darunavir shows a high genetic barrier to resistance development, and virus strains with lower sensitivity to darunavir have a higher number of PI resistance-associated mutations than viruses resistant to other PIs. In this work, we have enzymologically and structurally characterized a number of highly mutated clinically derived PRs with high levels of phenotypic resistance to darunavir. With 18 to 21 amino acid residue changes, the PR variants studied in this work are the most highly mutated HIV PR species ever studied by means of enzyme kinetics and X-ray crystallography. The recombinant proteins sho

SUBMITTER: Saskova KG 

PROVIDER: S-EPMC2738195 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature